IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030

IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030

2024.01.14
On July 23, 2023, the 12th International AIDS Society (IAS) HIV Science Conference, referred to as IAS 2023, officially began in Brisbane, Australia. As one of the largest open academic conferences in the global HIV and AIDS field, the event attracted participation from experts, medical professionals, community groups, and medical enterprises worldwide. The conference emphasized the importance of science as the foundation of policy and practice, highlighting the close integration of science, policy, and activism to promote significant advancements in the HIV and AIDS sector. The theme of the conference is "End Inequalities. End AIDS. End Pandemics.", reflecting IAS's ultimate vision. The goal is to rally health experts globally towards the shared ambition of eradicating AIDS by 2030.
APASL 2023 | Prof. Jia Jidong: Latest Advances in Primary Biliary Cholangitis

APASL 2023 | Prof. Jia Jidong: Latest Advances in Primary Biliary Cholangitis

2024.01.06
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease mediated by autoimmunity, with its pathogenesis not yet fully understood. Traditionally, PBC was thought to predominantly affect Western populations, but in recent decades, there has been an increasing number of reported cases and published literature in the Asia-Pacific region, escalating the disease burden. In response, the Asia-Pacific Association for the Study of the Liver (APASL) released clinical guidelines for PBC last year to better guide clinical practice. Recently, at the 32nd APASL Annual Conference, Professor Jia Jidong from the Capital Medical University Affiliated Beijing Friendship Hospital, China, delivered an insightful academic lecture titled "Latest Advances in Primary Biliary Cholangitis".
Exploration of Blinatumomab and Reduced Dosing of Cyclophosphamide before and after Allogeneic Hematopoietic Stem Cell Transplantation

Exploration of Blinatumomab and Reduced Dosing of Cyclophosphamide before and after Allogeneic Hematopoietic Stem Cell Transplantation

2024.01.05
The 65th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from December 9 to 12, 2023. ASH Annual Meeting is the largest and most comprehensive international event covering both basic and clinical research in hematology. This year, the Hematology Department at West China Hospital, Sichuan University, presented two oral reports, and we delve into these studies
“Optimizing Allo-HSCT Preconditioning Strategies for R/R AML and Elderly Myeloid Tumor Patients: Insights from Prof. Jiang Erlie’s Team”

“Optimizing Allo-HSCT Preconditioning Strategies for R/R AML and Elderly Myeloid Tumor Patients: Insights from Prof. Jiang Erlie’s Team”

2024.01.04
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) stands as a pivotal treatment for malignant hematological diseases. The preconditioning phase plays a crucial role in the overall transplantation process, influencing the eradication of residual tumor cells, enhancing transplant success rates, and reducing post-transplant complications and relapse rates. At the 65th Annual Meeting of the American Society of Hematology (ASH) in 2023, Professor Jiang Erlie's team from the Hematology Hospital of the Chinese Academy of Medical Sciences presented two studies focusing on optimizing and exploring preconditioning regimens for allo-HSCT in relapsed/refractory acute myeloid leukemia (R/R AML) and elderly myeloid tumor patients. This article shares the key findings and clinical significance of these two studies.
BCMA/CD19 Dual-Target FasTCAR-T Cells Efficient and Safe in First-Line Treatment of High-Risk Newly Diagnosed Multiple Myeloma Patients

BCMA/CD19 Dual-Target FasTCAR-T Cells Efficient and Safe in First-Line Treatment of High-Risk Newly Diagnosed Multiple Myeloma Patients

2024.01.04
At the 65th American Society of Hematology Annual Meeting in 2023 (ASH), Professor Du Juan and her team from Shanghai Changzheng Hospital presented preliminary findings from a Phase I study (abstract 1022) assessing the efficacy and safety of BCMA/CD19 dual-target FasTCAR-T cells (GC012F) in treating high-risk, newly diagnosed multiple myeloma (HR-NDMM) patients. The study was selected for oral presentation at the conference. In this article, "Tumor Insight" has compiled the abstract content and invited Professor Du Juan to provide commentary for readers' reference.
Professor Xiaojun Huang Awarded International Collaboration Award by IACH

Professor Xiaojun Huang Awarded International Collaboration Award by IACH

2024.01.04
Renowned hematologist Professor Xiaojun Huang has been honored with the International Collaboration Award by the International Academy for Clinical Hematology (IACH). Prof. Huang, a pioneer in the successful implementation of haploidentical transplantation, has significantly contributed to the field of clinical hematology and played a crucial role in promoting global collaboration. The award ceremony took place on October 5, 2023, during the IACH annual meeting held in Paris. Professor Mohamad Mohty, the current president of IACH, praised Xiaojun Huang 's outstanding achievements and key contributions to international collaboration in his invitation and award speech.
Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B

Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B

2023.12.21
Chronic hepatitis B is the leading cause of liver disease in Chinese children, posing a serious threat to their health. The "Sprout" project is China's first large-scale real-world study focusing on antiviral treatment for chronic hepatitis B in children. Led by Dr. Hongfei Zhang's team, with Shenzhen Third People's Hospital as the main center, the project is a charitable initiative initiated by the Beijing Chen Jumei Foundation. On November 10, 2023, the first day of the 2023 American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Dr. Hongfei Zhang's team from the Chen Jumei Medical Group presented the latest stage data of the "Sprout" project. The team's detailed introduction to the project and its progress is shared below.